Vaxcyte reports Q1 net loss $60.5M; VAX-24 Phase 2 meets endpoints in adults 65+

Vaxcyte, Inc.

2023-Q1 EPS reported -$0.70

Net loss of $60.5M in Q1 2023 vs $39.0M in Q1 2022; R&D expenses $58.1M, up from $31.7M.
Cash, cash equivalents and investments $949.9M as of March 31, 2023, excluding $545.1M net proceeds from recent public offering.
Positive Phase 2 data for VAX-24 in adults 65+: at 2.2mcg dose, met OPA non-inferiority for 18/20 common serotypes vs PCV20 and superiority for all 4 unique serotypes.
Dosed first participants in VAX-24 infant Phase 2 study; topline data expected by 2025.
Completed $575M follow-on public offering in April 2023; VAX-31 IND submission expected H2 2023, Phase 1/2 data in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vaxcyte, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 8, 2023, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-018818

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.